3-O-Methylquercetin

Name: 3-O-Methylquercetin
Brand: MedChemExpress
SKU: HY-N1860
Rating: 4.5 (0 reviews)

製品番号: HY-N1860 純度: 99.98%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

3-O-Methylquercetin is an inhibitor of cAMP and CGMP-phosphodiesterase (PDE) with IC₅₀ at 13.8 μM and 14.3 μM, respectively. 3-O-Methylquercetin is an inhibitor of β-secretase with an IC₅₀ of 6.5 μM. 3-O-Methylquercetin has a neuroprotective effect against neuronal death caused by oxidative damage. 3-O-Methylquercetin has strong antiviral activity against poliovirus, coxsackie virus and human rhinovirus. 3-O-Methylquercetin has anti-inflammatory and trachea-relaxing effects and can be used in the study of inflammatory diseases and asthma.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

3-O-Methylquercetin 構造式

CAS 番号 : 1486-70-0

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 275	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 275	在庫あり	Estimated Time of Arrival: December 31
Solid
1 mg	$110	在庫あり	Estimated Time of Arrival: December 31
5 mg	$250	在庫あり	Estimated Time of Arrival: December 31
10 mg	$356	在庫あり	Estimated Time of Arrival: December 31
25 mg	$610	在庫あり	Estimated Time of Arrival: December 31
50 mg		お問い合わせ
100 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

Phosphodiesterase (PDE) アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

PDE1 PDE2 PDE3 PDE4 PDE5 PDE6 PDE7 PDE9 PDE10 PDE11 PDE12 PDE8 Autotaxin

NO Synthase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

nNOS iNOS eNOS

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	8.14 μM Compound: 2a	Anticancer activity against human A549 cells by HTS assay Anticancer activity against human A549 cells by HTS assay	[PMID: 25139569]
BV-2	IC₅₀	3.8 μM Compound: 104	Anti-inflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay Anti-inflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay	[PMID: 37683361]
BV-2	IC₅₀	3.8 μM Compound: 3, 3-O-methylquercetin	Inhibition of LPS-induced NO production in mouse BV2 cells Inhibition of LPS-induced NO production in mouse BV2 cells	[PMID: 18178435]
Calu-1	IC₅₀	>50 μM Compound: 2a	Anticancer activity against human Calu1 cells by HTS assay Anticancer activity against human Calu1 cells by HTS assay	[PMID: 25139569]
HeLa	IC₅₀	6.09 μM Compound: 2a	Anticancer activity against human HeLa cells by HTS assay Anticancer activity against human HeLa cells by HTS assay	[PMID: 25139569]
HepG2 2.2.15	CC₅₀	2.1 μM Compound: Table 3, R9C1	Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay	[PMID: 21401115]
HOP-62	IC₅₀	35.54 μM Compound: 2a	Anticancer activity against human HOP62 cells by HTS assay Anticancer activity against human HOP62 cells by HTS assay	[PMID: 25139569]
KB	ED₅₀	17 μg/mL Compound: NSC-154016	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 469554]
LOX IMVI	IC₅₀	>50 μM Compound: 2a	Anticancer activity against human LOXIMVI cells by HTS assay Anticancer activity against human LOXIMVI cells by HTS assay	[PMID: 25139569]
M14	IC₅₀	>50 μM Compound: 2a	Anticancer activity against human M14 cells by HTS assay Anticancer activity against human M14 cells by HTS assay	[PMID: 25139569]
Monocyte	IC₅₀	47 μM Compound: 3-O-methyl quercetin	Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA	[PMID: 10096854]
NCI-H1299	IC₅₀	46.81 μM Compound: 2a	Anticancer activity against human H1299 cells by HTS assay Anticancer activity against human H1299 cells by HTS assay	[PMID: 25139569]
NCI-H157	IC₅₀	18.67 μM Compound: 2a	Anticancer activity against human NCI-H157 cells by HTS assay Anticancer activity against human NCI-H157 cells by HTS assay	[PMID: 25139569]
NCI-H1792	IC₅₀	24.09 μM Compound: 2a	Anticancer activity against human NCI-H1792 cells by HTS assay Anticancer activity against human NCI-H1792 cells by HTS assay	[PMID: 25139569]
NCI-H1944	IC₅₀	23.64 μM Compound: 2a	Anticancer activity against human NCI-H1944 cells by HTS assay Anticancer activity against human NCI-H1944 cells by HTS assay	[PMID: 25139569]
NCI-H460	IC₅₀	9.91 μM Compound: 2a	Anticancer activity against human H460 cells by HTS assay Anticancer activity against human H460 cells by HTS assay	[PMID: 25139569]
NCI-H522	IC₅₀	>50 μM Compound: 2a	Anticancer activity against human NCI-H522 cells by HTS assay Anticancer activity against human NCI-H522 cells by HTS assay	[PMID: 25139569]
RAW264.7	IC₅₀	3.5 μg/mL Compound: 204	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent based assay	[PMID: 31255927]

体外実験

3-O-Methylquercetin (1-10 μM; 24 h) inhibits NO production (IC₅₀: 4.23μM) and the expression of iNOS protein and mRNA in a concentration-dependent manner in RAW 264.7 cells treated with LPS (HY-D1056)^[1].
3-O-Methylquercetin (1-30 μM; 15 min) can relax the trachea of guinea pig^[2].
3-o-methylquercetin (1-100 μM；20-24 h) improves the survival rate of rat cortical cells treated with H₂O₂^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	LPS (HY-D1056) treated RAW 264.7
Concentration:	1, 3 and 10 μM
Incubation Time:	24 h
Result:	Reduced the level of iNOS in a dose-dependent manner.

体内実験

3-O-Methylquercetin (3-30 μmol/kg ≈ 0.95-9.5 mg/kg; Intraperitoneal injection; 3 times) shows improvement in airway hyperresponsiveness induced by oobumin (HY-W250978)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ovalbumin (HY-W250978) treated female BALB/c mice aged 8-12 weeks old^[4]
Dosage:	3 and 30 μmol/kg ≈ 0.95 and 9.5 mg/kg
Administration:	Intraperitoneal injection (i.p.); 3 times
Result:	Significantly suppressed the enhanced pause value induced by aerosolized methacholine in sensitized mice after secondary allergen challenge. Significantly suppressed total inflammatory cells, macrophages, neutrophils, and eosinophils, but not lymphocytes. Significantly decreased the secretion of TNF-α, and at the highest dose even decreased the secretions of IL-4, IL-5, and TNF-α.

分子量

316.26

分子式

C₁₆H₁₂O₇

CAS 番号

1486-70-0

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1C(OC)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13

Structure Classification

Initial Source

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (158.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.1620 mL	15.8098 mL	31.6196 mL
5 mM	0.6324 mL	3.1620 mL	6.3239 mL
10 mM	0.3162 mL	1.5810 mL	3.1620 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 0.62 mg/mL (1.96 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 0.62 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.2 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 0.62 mg/mL (1.96 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 0.62 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.2 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: 0.62 mg/mL (1.96 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 0.62 mg/mL. If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.2 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.98%

Select Batch:

データシート (278 KB) SDS (480 KB)

COA (249 KB) HNMR (175 KB) CNMR (179 KB) RP-HPLC (335 KB) MS (462 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Jiang JS, et al. Mechanisms of suppression of nitric oxide production by 3-O-methylquercetin in RAW 264.7 cells. J Ethnopharmacol. 2006 Jan 16;103(2):281-7. [Content Brief]

[2]. Ko WC, et al. Mechanisms of relaxant action of 3-O-methylquercetin in isolated guinea pig trachea. Planta Med. 2002 Jan;68(1):30-5. [Content Brief]

[3]. Kim SH, et al. Glucose-containing flavones--their synthesis and antioxidant and neuroprotective activities. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6009-13. [Content Brief]

[4]. Ko WC, et al. Suppressive effects of 3-O-methylquercetin on ovalbumin-induced airway hyperresponsiveness. Planta Med. 2004 Dec;70(12):1123-7. [Content Brief]

[5]. Mugabowindekwe, et al. Universiteit Antwerpen (Belgium) ProQuest Dissertations & Theses, 2004. 3141550.

[6]. Zhumanova K, et al. Inhibitory mechanism of O-methylated quercetins, highly potent β-secretase inhibitors isolated from Caragana balchaschensis (Kom.) Pojark. J Ethnopharmacol. 2021 May 23;272:113935. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.1620 mL	15.8098 mL	31.6196 mL	79.0489 mL
	5 mM	0.6324 mL	3.1620 mL	6.3239 mL	15.8098 mL
	10 mM	0.3162 mL	1.5810 mL	3.1620 mL	7.9049 mL
	15 mM	0.2108 mL	1.0540 mL	2.1080 mL	5.2699 mL
	20 mM	0.1581 mL	0.7905 mL	1.5810 mL	3.9524 mL
	25 mM	0.1265 mL	0.6324 mL	1.2648 mL	3.1620 mL
	30 mM	0.1054 mL	0.5270 mL	1.0540 mL	2.6350 mL
	40 mM	0.0790 mL	0.3952 mL	0.7905 mL	1.9762 mL
	50 mM	0.0632 mL	0.3162 mL	0.6324 mL	1.5810 mL
	60 mM	0.0527 mL	0.2635 mL	0.5270 mL	1.3175 mL
	80 mM	0.0395 mL	0.1976 mL	0.3952 mL	0.9881 mL
	100 mM	0.0316 mL	0.1581 mL	0.3162 mL	0.7905 mL